GLP-1 receptor agonists × adverse events & safety

TrialDiabetes care2025

Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.

Daniel S Hsia et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 9,877 people · 2025

Randomised comparison

Lowered adverse events & safety

−22%−34% to −8%

Bigger than 5 in 10 for adverse events & safety

As reported

HR 0.78, 95% CI 0.66–0.92

One number in the abstract

the abstract, start to end

in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P =

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
HR 0.780.66–0.92
GLP-1 receptor agonistsSulfonylureas & glinidesAdverse events & safety

GLP-1 receptor agonists × adverse events & safetyharms?mixed

unlikelylikely
0.020.02 without it

Sulfonylureas & glinides × adverse events & safetyharms?mixed

unlikelylikely
0.000.25 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

Not cited yet

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 40424051